Otros idiomas Johnson & Johnson

Acciones

JNJ

US4781601046

Tiempo real estimado Cboe BZX Otros sitios de cotización 21:14:45 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
145,2 ^USD	-1,10 %		-2,98 %	-7,42 %

29/04	J&J y Bristol Myers pierden las impugnaciones al programa de negociación de precios de medicamentos de EE.UU.	RE
26/04	Johnson & Johnson dice que el CHMP europeo recomienda la aprobación de Rybrevant más quimioterapia para el tratamiento del cáncer de pulmón	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	17:18
J&J : le CHMP recommande une AMM standard pour Sirturo	17:10
Après Microsoft, Alphabet, Tesla et Apple, Amazon doit faire le job	09:02
En Direct des Marchés : Thales, Stellantis, Capgemini, Atos, VusionGroup, Orpea, Adidas, HSBC...	08:42
J&J, Bristol Myers lose challenges to US drug price negotiation program	29/04
Bourse Zurich: le SMI s'approche des 11'400 points puis replonge dans le rouge	29/04
J&J : avis positif du CHMP pour le cancer du poumon	29/04
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure	29/04
Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment	26/04
Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations	26/04
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar	26/04
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	24/04
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	24/04
Welfare Plan Class Action Litigation Underscores Importance Of Minding Your Fiduciary Duties	24/04
Johnson & Johnson to participate in the Bernstein's 40th Annual Strategic Decisions Conference	23/04
Janssen - CARVYKTI is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy	23/04
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)	22/04
J&J : feu vert de l'UE pour Carvykti dans le myélome multiple	22/04
Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy	22/04
Contaminated cough syrup in Africa no longer available - WHO	22/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Joseph Wolk, Director Financiero de J&J: Fin de la patente de su medicamento estrella

23 de enero 2024 a las 18:30